0
     

Report Added
Report already added
Global Biosimilars Market 2020-2030 by Product Type (Non-glycosylated, Glycosylated), Indication (Cancer, Autoimmune Disease, Blood Disorder, Diabetes), Manufacturing (Contract, Inhouse), End User (Hospitals and Clinics, Research Institutes), and Region: Trend Forecast and Growth Opportunity

Global Biosimilars Market 2020-2030 by Product Type (Non-glycosylated, Glycosylated), Indication (Cancer, Autoimmune Disease, Blood Disorder, Diabetes), Manufacturing (Contract, Inhouse), End User (Hospitals and Clinics, Research Institutes), and Region: Trend Forecast and Growth Opportunity

Global biosimilars market will reach $113.25 billion by 2030, growing by 25.7% annually over 2020-2030 driven by the affordability of biosimilar-based treatment, rising incidence of chronic diseases due to aging populations, patent expirations of many blockbuster drugs, and better healthcare provisions.

Highlighted with 89 tables and 90 figures, this 180-page report “Global Biosimilars Market 2020-2030 by Product Type (Non-glycosylated, Glycosylated), Indication (Cancer, Autoimmune Disease, Blood Disorder, Diabetes), Manufacturing (Contract, Inhouse), End User (Hospitals and Clinics, Research Institutes), and Region: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire global biosimilars market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19).

In-depth qualitative analyses include identification and investigation of the following aspects:
•Market Structure
•Growth Drivers
•Restraints and Challenges
•Emerging Product Trends & Market Opportunities
•Porter’s Fiver Forces

The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global biosimilars market in every aspect of the classification from perspectives of Product Type, Indication, Manufacturing, End User, and Region.

Based on Product Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.
•Recombinant Non-glycosylated Biosimilars
-Insulin
-Recombinant Human Growth Hormone (rHGH)
-Granulocyte Colony Stimulating Factor
-Interferon
•Recombinant Glycosylated Biosimilars
-Monoclonal Antibodies (mAb)
-Erythropoietin (EPO)
-Follicle Stimulating Hormone
•Recombinant Peptides and Others
-Tumor Necrosis Factor (TNF)-Inhibitor
-Parathyroid Hormone
-Enzymes, Immunomodulators, GnRH Analogs and Others

Based on Indication, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.
•Cancer
•Autoimmune Disease
•Blood Disorder
•Diabetes
•Growth Hormone Deficiency
•Infectious Diseases
•Other Indications

Based on Manufacturing, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.
•Contract Manufacturing
•Inhouse Manufacturing

Based on End User, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.
•Hospitals and Clinics
•Research Institutes
•Other End Users

Geographically, the following regions together with the listed national/local markets are fully investigated:
•North America (U.S., Canada, and Mexico)
•Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
•APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
•South America (Brazil, Chile, Argentina, Rest of South America)
•MEA (Turkey, Iran, South Africa)

For each aforementioned region and country, detailed analysis and data for annual revenue ($ mn) are available for 2019-2030. The breakdown of all regional markets by country and split of key national markets by Product Type, Indication, and End User over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Key Players (this may not be a complete list and extra companies can be added upon request):
AMEGA Biotech S.A.
Apotex Inc.
Biocon Ltd
Biogen Inc.
Boehringer Ingelheim
Celltrion, Inc.
Dr. Reddy’s Laboratories Ltd.
Eli Lilly and Company
Intas Pharmaceuticals Ltd.
LG Chem, Ltd.
Merck and Co. Inc.
Mylan N.V.
Pfizer Inc.
Samsung Biologics Co., Ltd.
Sandoz International GmbH
STADA Arzneimittel AG
Teva Pharmaceutical Industries Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

1 Introduction9
1.1 Industry Definition and Research Scope9
1.1.1 Industry Definition9
1.1.2 Research Scope10
1.2 Research Methodology13
1.2.1 Overview of Market Research Methodology13
1.2.2 Market Assumption14
1.2.3 Secondary Data14
1.2.4 Primary Data14
1.2.5 Data Filtration and Model Design15
1.2.6 Market Size/Share Estimation16
1.2.7 Research Limitations17
1.3 Executive Summary18
2 Market Overview and Dynamics20
2.1 Market Size and Forecast20
2.1.1 Impact of COVID-19 on World Economy23
2.1.2 Impact of COVID-19 on the Market26
2.2 Major Growth Drivers28
2.3 Market Restraints and Challenges33
2.4 Emerging Opportunities and Market Trends36
2.5 Porter’s Fiver Forces Analysis40
3 Segmentation of Global Market by Product Type44
3.1 Market Overview by Product Type44
3.2 Recombinant Non-glycosylated Biosimilars46
3.2.1 Insulin48
3.2.2 Recombinant Human Growth Hormone (rHGH)49
3.2.3 Granulocyte Colony Stimulating Factor50
3.2.4 Interferon51
3.3 Recombinant Glycosylated Biosimilars52
3.3.1 Monoclonal Antibodies (mAb)53
3.3.2 Erythropoietin (EPO)54
3.3.3 Follicle Stimulating Hormone55
3.4 Recombinant Peptides and Others56
3.4.1 Tumor Necrosis Factor (TNF)-Inhibitor57
3.4.2 Parathyroid Hormone58
3.4.3 Enzymes, Immunomodulators, GnRH Analogs and Others59
4 Segmentation of Global Market by Indication60
4.1 Market Overview by Indication60
4.2 Cancer62
4.3 Autoimmune Disease63
4.4 Blood Disorder64
4.5 Diabetes65
4.6 Growth Hormone Deficiency66
4.7 Infectious Diseases67
4.8 Other Indications68
5 Segmentation of Global Market by Manufacturing69
5.1 Market Overview by Manufacturing69
5.2 Contract Manufacturing71
5.3 Inhouse Manufacturing72
6 Segmentation of Global Market by End User73
6.1 Market Overview by End User73
6.2 Hospitals and Clinics75
6.3 Research Institutes76
6.4 Other End Users77
7 Segmentation of Global Market by Region78
7.1 Geographic Market Overview 2019-203078
7.2 North America Market 2019-2030 by Country82
7.2.1 Overview of North America Market82
7.2.2 U.S.86
7.2.3 Canada96
7.2.4 Mexico98
7.3 European Market 2019-2030 by Country100
7.3.1 Overview of European Market100
7.3.2 Germany106
7.3.3 U.K.108
7.3.4 France110
7.3.5 Spain112
7.3.6 Italy114
7.3.7 Russia116
7.3.8 Rest of European Market118
7.4 Asia-Pacific Market 2019-2030 by Country120
7.4.1 Overview of Asia-Pacific Market120
7.4.2 Japan124
7.4.3 China127
7.4.4 Australia129
7.4.5 India131
7.4.6 South Korea133
7.4.7 Rest of APAC Region135
7.5 South America Market 2019-2030 by Country137
7.5.1 Argentina140
7.5.2 Brazil142
7.5.3 Chile144
7.5.4 Rest of South America Market146
7.6 MEA Market 2019-2030 by Country147
7.6.1 Turkey150
7.6.2 Iran152
7.6.3 South Africa154
7.6.4 Other National Markets156
8 Competitive Landscape157
8.1 Overview of Key Vendors157
8.2 New Product Launch, Partnership, Investment, and M&A161
8.3 Company Profiles162
AMEGA Biotech S.A.162
Apotex Inc.164
Biocon Ltd165
Biogen Inc.166
Boehringer Ingelheim167
Celltrion, Inc.168
Dr. Reddy’s Laboratories Ltd.169
Eli Lilly and Company170
Intas Pharmaceuticals Ltd.171
LG Chem, Ltd.172
Merck and Co. Inc.173
Mylan N.V.174
Pfizer Inc.175
Samsung Biologics Co., Ltd.176
Sandoz International GmbH177
STADA Arzneimittel AG178
Teva Pharmaceutical Industries Ltd.179
RELATED REPORTS180

List of Tables:
Table 1. Snapshot of Global Biosimilars Market in Balanced Perspective, 2019-203019
Table 2. Growth Rate of World GDP, 2020-202224
Table 3. World Health Spending by Region, $ bn, 2013-202032
Table 4. Main Product Trends and Market Opportunities in Global Biosimilars Market36
Table 5. Global Biosimilars Market by Product Type, 2019-2030, $ mn44
Table 6. Global Biosimilars Market: Recombinant Non-glycosylated Biosimilars by Product, 2019-2030, $ mn47
Table 7. Global Biosimilars Market: Recombinant Glycosylated Biosimilars by Product, 2019-2030, $ mn52
Table 8. Global Biosimilars Market: Recombinant Peptides and Others by Product, 2019-2030, $ mn56
Table 9. Global Biosimilars Market by Indication, 2019-2030, $ mn60
Table 10. Global Biosimilars Market by Manufacturing, 2019-2030, $ mn69
Table 11. Global Biosimilars Market by End User, 2019-2030, $ mn73
Table 12. Global Biosimilars Market by Region, 2019-2030, $ mn79
Table 13. Leading National Biosimilars Market, 2019 and 2030F, $ mn81
Table 14. North America Biosimilars Market by Country, 2019-2030, $ mn84
Table 15. U.S. Biosimilars Market by Product Type, 2019-2030, $ mn89
Table 16. U.S. Biosimilars Market by Indication, 2019-2030, $ mn89
Table 17. U.S. Biosimilars Market by End User, 2019-2030, $ mn89
Table 18. FDA Approved Biosimilars in U.S., 2015-202090
Table 19. U.S. Select Pending Biosimilar BLAs as of December 202094
Table 20. U.S. Biosimilar Market Share (market share data through July 2020)95
Table 21. Canada Biosimilars Market by Product Type, 2019-2030, $ mn97
Table 22. Canada Biosimilars Market by Indication, 2019-2030, $ mn97
Table 23. Canada Biosimilars Market by End User, 2019-2030, $ mn97
Table 24. Mexico Biosimilars Market by Product Type, 2019-2030, $ mn99
Table 25. Mexico Biosimilars Market by Indication, 2019-2030, $ mn99
Table 26. Mexico Biosimilars Market by End User, 2019-2030, $ mn99
Table 27. Europe Biosimilars Market by Country, 2019-2030, $ mn103
Table 28. Approved Biosimilars in Europe104
Table 29. Germany Biosimilars Market by Product Type, 2019-2030, $ mn107
Table 30. Germany Biosimilars Market by Indication, 2019-2030, $ mn107
Table 31. Germany Biosimilars Market by End User, 2019-2030, $ mn107
Table 32. U.K. Biosimilars Market by Product Type, 2019-2030, $ mn109
Table 33. U.K. Biosimilars Market by Indication, 2019-2030, $ mn109
Table 34. U.K. Biosimilars Market by End User, 2019-2030, $ mn109
Table 35. France Biosimilars Market by Product Type, 2019-2030, $ mn111
Table 36. France Biosimilars Market by Indication, 2019-2030, $ mn111
Table 37. France Biosimilars Market by End User, 2019-2030, $ mn111
Table 38. Spain Biosimilars Market by Product Type, 2019-2030, $ mn113
Table 39. Spain Biosimilars Market by Indication, 2019-2030, $ mn113
Table 40. Spain Biosimilars Market by End User, 2019-2030, $ mn113
Table 41. Italy Biosimilars Market by Product Type, 2019-2030, $ mn115
Table 42. Italy Biosimilars Market by Indication, 2019-2030, $ mn115
Table 43. Italy Biosimilars Market by End User, 2019-2030, $ mn115
Table 44. Russia Biosimilars Market by Product Type, 2019-2030, $ mn117
Table 45. Russia Biosimilars Market by Indication, 2019-2030, $ mn117
Table 46. Russia Biosimilars Market by End User, 2019-2030, $ mn117
Table 47. Biosimilars Market in Rest of Europe by Country, 2019-2030, $ mn119
Table 48. APAC Biosimilars Market by Country, 2019-2030, $ mn122
Table 49. Japan Biosimilars Market by Product Type, 2019-2030, $ mn126
Table 50. Japan Biosimilars Market by Indication, 2019-2030, $ mn126
Table 51. Japan Biosimilars Market by End User, 2019-2030, $ mn126
Table 52. China Biosimilars Market by Product Type, 2019-2030, $ mn128
Table 53. China Biosimilars Market by Indication, 2019-2030, $ mn128
Table 54. China Biosimilars Market by End User, 2019-2030, $ mn128
Table 55. Australia Biosimilars Market by Product Type, 2019-2030, $ mn130
Table 56. Australia Biosimilars Market by Indication, 2019-2030, $ mn130
Table 57. Australia Biosimilars Market by End User, 2019-2030, $ mn130
Table 58. India Biosimilars Market by Product Type, 2019-2030, $ mn132
Table 59. India Biosimilars Market by Indication, 2019-2030, $ mn132
Table 60. India Biosimilars Market by End User, 2019-2030, $ mn132
Table 61. South Korea Biosimilars Market by Product Type, 2019-2030, $ mn134
Table 62. South Korea Biosimilars Market by Indication, 2019-2030, $ mn134
Table 63. South Korea Biosimilars Market by End User, 2019-2030, $ mn134
Table 64. Biosimilars Market in Rest of APAC by Country/Region, 2019-2030, $ mn136
Table 65. South America Biosimilars Market by Country, 2019-2030, $ mn139
Table 66. Argentina Biosimilars Market by Product Type, 2019-2030, $ mn141
Table 67. Argentina Biosimilars Market by Indication, 2019-2030, $ mn141
Table 68. Argentina Biosimilars Market by End User, 2019-2030, $ mn141
Table 69. Brazil Biosimilars Market by Product Type, 2019-2030, $ mn143
Table 70. Brazil Biosimilars Market by Indication, 2019-2030, $ mn143
Table 71. Brazil Biosimilars Market by End User, 2019-2030, $ mn143
Table 72. Chile Biosimilars Market by Product Type, 2019-2030, $ mn145
Table 73. Chile Biosimilars Market by Indication, 2019-2030, $ mn145
Table 74. Chile Biosimilars Market by End User, 2019-2030, $ mn145
Table 75. MEA Biosimilars Market by Country, 2019-2030, $ mn149
Table 76. Turkey Biosimilars Market by Product Type, 2019-2030, $ mn151
Table 77. Turkey Biosimilars Market by Indication, 2019-2030, $ mn151
Table 78. Turkey Biosimilars Market by End User, 2019-2030, $ mn151
Table 79. Iran Biosimilars Market by Product Type, 2019-2030, $ mn153
Table 80. Iran Biosimilars Market by Indication, 2019-2030, $ mn153
Table 81. Iran Biosimilars Market by End User, 2019-2030, $ mn153
Table 82. South Africa Biosimilars Market by Product Type, 2019-2030, $ mn155
Table 83. South Africa Biosimilars Market by Indication, 2019-2030, $ mn155
Table 84. South Africa Biosimilars Market by End User, 2019-2030, $ mn155
Table 85. Breakdown of World Market by Key Vendor, 2020, %159
Table 86. AMEGA Biotech S.A.: Company Snapshot162
Table 87. AMEGA Biotech S.A.: Business Segmentation162
Table 88. AMEGA Biotech S.A.: Product Portfolio163
Table 89. AMEGA Biotech S.A.: Revenue, 2018-2020, $ mn163

List of Figures:
Figure 1. Research Method Flow Chart13
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation16
Figure 3. Global Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-203018
Figure 4. Global Biosimilars Market, 2019-2030, $ mn20
Figure 5. EMA and FDA Biosimilar Approvals, 2015 - 201921
Figure 6. EMA-approved Biosimilars Distribution by Reference Product and Therapeutic Area21
Figure 7. FDA-approved Biosimilars Distribution by Reference Product and Therapeutic Area22
Figure 8. Impact of COVID-19 on Business26
Figure 9. Primary Drivers and Impact Factors of Global Biosimilars Market28
Figure 10. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million31
Figure 11. World Population 65 and Over, % of Total Population, 1950-206031
Figure 12. Primary Restraints and Impact Factors of Global Biosimilars Market33
Figure 13. Investment Opportunity Analysis37
Figure 14. Porter’s Fiver Forces Analysis of Global Biosimilars Market40
Figure 15. Breakdown of Global Biosimilars Market by Product Type, 2019-2030, % of Revenue45
Figure 16. Global Addressable Market Cap in 2021-2030 by Product Type, Value ($ mn) and Share (%)45
Figure 17. Global Biosimilars Market by Product Type: Recombinant Non-glycosylated Biosimilars, 2019-2030, $ mn46
Figure 18. Global Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Insulin, 2019-2030, $ mn48
Figure 19. Global Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Recombinant Human Growth Hormone (rHGH), 2019-2030, $ mn49
Figure 20. Global Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Granulocyte Colony Stimulating Factor, 2019-2030, $ mn50
Figure 21. Global Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Interferon, 2019-2030, $ mn51
Figure 22. Global Biosimilars Market by Product Type: Recombinant Glycosylated Biosimilars, 2019-2030, $ mn52
Figure 23. Global Biosimilars Market by Recombinant Glycosylated Biosimilars: Monoclonal Antibodies (mAb), 2019-2030, $ mn53
Figure 24. Global Biosimilars Market by Recombinant Glycosylated Biosimilars: Erythropoietin (EPO), 2019-2030, $ mn54
Figure 25. Global Biosimilars Market by Recombinant Glycosylated Biosimilars: Follicle Stimulating Hormone, 2019-2030, $ mn55
Figure 26. Global Biosimilars Market by Product Type: Recombinant Peptides and Others, 2019-2030, $ mn56
Figure 27. Global Biosimilars Market by Recombinant Peptides and Others: Tumor Necrosis Factor (TNF)-Inhibitor, 2019-2030, $ mn57
Figure 28. Global Biosimilars Market by Recombinant Peptides and Others: Parathyroid Hormone, 2019-2030, $ mn58
Figure 29. Global Biosimilars Market by Recombinant Peptides and Others: Enzymes, Immunomodulators, GnRH Analogs and Others, 2019-2030, $ mn59
Figure 30. Breakdown of Global Biosimilars Market by Indication, 2019-2030, % of Sales Revenue61
Figure 31. Global Addressable Market Cap in 2021-2030 by Indication, Value ($ mn) and Share (%)61
Figure 32. Global Biosimilars Market by Indication: Cancer, 2019-2030, $ mn62
Figure 33. Global Biosimilars Market by Indication: Autoimmune Disease, 2019-2030, $ mn63
Figure 34. Global Biosimilars Market by Indication: Blood Disorder, 2019-2030, $ mn64
Figure 35. Global Biosimilars Market by Indication: Diabetes, 2019-2030, $ mn65
Figure 36. Global Biosimilars Market by Indication: Growth Hormone Deficiency, 2019-2030, $ mn66
Figure 37. Global Biosimilars Market by Indication: Infectious Diseases, 2019-2030, $ mn67
Figure 38. Global Biosimilars Market by Indication: Other Indications, 2019-2030, $ mn68
Figure 39. Breakdown of Global Biosimilars Market by Manufacturing, 2019-2030, % of Sales Revenue70
Figure 40. Global Addressable Market Cap in 2021-2030 by Manufacturing, Value ($ mn) and Share (%)70
Figure 41. Global Biosimilars Market by Manufacturing: Contract Manufacturing, 2019-2030, $ mn71
Figure 42. Global Biosimilars Market by Manufacturing: Inhouse Manufacturing, 2019-2030, $ mn72
Figure 43. Breakdown of Global Biosimilars Market by End User, 2019-2030, % of Revenue74
Figure 44. Global Addressable Market Cap in 2021-2030 by End User, Value ($ mn) and Share (%)74
Figure 45. Global Biosimilars Market by End User: Hospitals and Clinics, 2019-2030, $ mn75
Figure 46. Global Biosimilars Market by End User: Research Institutes, 2019-2030, $ mn76
Figure 47. Global Biosimilars Market by End User: Other End Users, 2019-2030, $ mn77
Figure 48. Global Market Snapshot by Region78
Figure 49. Geographic Spread of Worldwide Biosimilars Market, 2019-2030, % of Sales Revenue79
Figure 50. Global Addressable Market Cap in 2021-2030 by Region, Value ($ mn) and Share (%)80
Figure 51. North American Biosimilars Market, 2019-2030, $ mn83
Figure 52. Breakdown of North America Biosimilars Market by Country, 2019 and 2030, % of Revenue84
Figure 53. Contribution to North America 2021-2030 Cumulative Market by Country, Value ($ mn) and Share (%)85
Figure 54. U.S. Biosimilars Market, 2019-2030, $ mn87
Figure 55. Biosimilar Approvals and Launches in U.S., 2015-202087
Figure 56. Canada Biosimilars Market, 2019-2030, $ mn96
Figure 57. Biosimilars Market in Mexico, 2019-2030, $ mn98
Figure 58. European Biosimilars Market, 2019-2030, $ mn101
Figure 59. Breakdown of European Biosimilars Market by Country, 2019 and 2030, % of Revenue102
Figure 60. Contribution to Europe 2021-2030 Cumulative Market by Country, Value ($ mn) and Share (%)103
Figure 61. Biosimilars Market in Germany, 2019-2030, $ mn106
Figure 62. Biosimilars Market in U.K., 2019-2030, $ mn108
Figure 63. Biosimilars Market in France, 2019-2030, $ mn110
Figure 64. Biosimilars Market in Spain, 2019-2030, $ mn112
Figure 65. Biosimilars Market in Italy, 2019-2030, $ mn114
Figure 66. Biosimilars Market in Russia, 2019-2030, $ mn116
Figure 67. Biosimilars Market in Rest of Europe, 2019-2030, $ mn118
Figure 68. Asia-Pacific Biosimilars Market, 2019-2030, $ mn121
Figure 69. Breakdown of APAC Biosimilars Market by Country, 2019 and 2030, % of Revenue121
Figure 70. Contribution to APAC 2021-2030 Cumulative Market by Country, Value ($ mn) and Share (%)123
Figure 71. Biosimilars Market in Japan, 2019-2030, $ mn125
Figure 72. Biosimilars Market in China, 2019-2030, $ mn127
Figure 73. Biosimilars Market in Australia, 2019-2030, $ mn129
Figure 74. Biosimilars Market in India, 2019-2030, $ mn131
Figure 75. Biosimilars Market in South Korea, 2019-2030, $ mn133
Figure 76. Biosimilars Market in Rest of APAC, 2019-2030, $ mn135
Figure 77. South America Biosimilars Market, 2019-2030, $ mn138
Figure 78. Breakdown of South America Biosimilars Market by Country, 2019 and 2030, % of Revenue138
Figure 79. Contribution to South America 2021-2030 Cumulative Market by Country, Value ($ mn) and Share (%)139
Figure 80. Biosimilars Market in Argentina, 2019-2030, $ mn140
Figure 81. Biosimilars Market in Brazil, 2019-2030, $ mn142
Figure 82. Biosimilars Market in Chile, 2019-2030, $ mn144
Figure 83. Biosimilars Market in Rest of South America, 2019-2030, $ mn146
Figure 84. Biosimilars Market in Middle East and Africa (MEA), 2019-2030, $ mn148
Figure 85. Breakdown of MEA Biosimilars Market by Country, 2019 and 2030, % of Revenue148
Figure 86. Contribution to MEA 2021-2030 Cumulative Market by Country, Value ($ mn) and Share (%)149
Figure 87. Biosimilars Market in Turkey, 2019-2030, $ mn150
Figure 88. Biosimilars Market in Iran, 2019-2030, $ mn152
Figure 89. Biosimilars Market in South Africa, 2019-2030, $ mn154
Figure 90. Growth Stage of Global Biosimilars Industry over the Forecast Period157

Report Title: Global Biosimilars Market 2020-2030 by Product Type (Non-glycosylated, Glycosylated), Indication (Cancer, Autoimmune Disease, Blood Disorder, Diabetes), Manufacturing (Contract, Inhouse), End User (Hospitals and Clinics, Research Institutes), and Region: Trend Forecast and Growth Opportunity


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

2021-2026 Vietnam Virology, Bacteriology, Parasitology and Mycology Testing Database: Supplier Shares, Volume and Sales Segment Forecasts for 100 Respiratory, STD, Gastrointestinal and Other Tests

2021-2026 Vietnam Virology, Bacteriology, Parasitology and Mycology Testing Database: Supplier Shares, Volume and Sales Segment Forecasts for 100 Respiratory, STD, Gastrointestinal and Other Tests


2021-2026 Venezuela Virology, Bacteriology, Parasitology and Mycology Testing Database: Supplier Shares, Volume and Sales Segment Forecasts for 100 Respiratory, STD, Gastrointestinal and Other Tests

2021-2026 Venezuela Virology, Bacteriology, Parasitology and Mycology Testing Database: Supplier Shares, Volume and Sales Segment Forecasts for 100 Respiratory, STD, Gastrointestinal and Other Tests


2021-2026 Uruguay Virology, Bacteriology, Parasitology and Mycology Testing Database: Supplier Shares, Volume and Sales Segment Forecasts for 100 Respiratory, STD, Gastrointestinal and Other Tests

2021-2026 Uruguay Virology, Bacteriology, Parasitology and Mycology Testing Database: Supplier Shares, Volume and Sales Segment Forecasts for 100 Respiratory, STD, Gastrointestinal and Other Tests


2021-2026 United Arab Emirates Virology, Bacteriology, Parasitology and Mycology Testing Database: Supplier Shares, Volume and Sales Segment Forecasts for 100 Respiratory, STD, Gastrointestinal and Other Tests

2021-2026 United Arab Emirates Virology, Bacteriology, Parasitology and Mycology Testing Database: Supplier Shares, Volume and Sales Segment Forecasts for 100 Respiratory, STD, Gastrointestinal and Other Tests


2021-2026 Ukraine Virology, Bacteriology, Parasitology and Mycology Testing Database: Supplier Shares, Volume and Sales Segment Forecasts for 100 Respiratory, STD, Gastrointestinal and Other Tests

2021-2026 Ukraine Virology, Bacteriology, Parasitology and Mycology Testing Database: Supplier Shares, Volume and Sales Segment Forecasts for 100 Respiratory, STD, Gastrointestinal and Other Tests


2021-2026 Turkey Virology, Bacteriology, Parasitology and Mycology Testing Database: Supplier Shares, Volume and Sales Segment Forecasts for 100 Respiratory, STD, Gastrointestinal and Other Tests

2021-2026 Turkey Virology, Bacteriology, Parasitology and Mycology Testing Database: Supplier Shares, Volume and Sales Segment Forecasts for 100 Respiratory, STD, Gastrointestinal and Other Tests